Therapy Directory

Azacitidine clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Azacitidine as a study intervention. Browse Azacitidine recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

695

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Solid Tumors, Advanced Malignancies, Metastatic Cancer
Interventions: Azacitidine, Pembrolizumab, Epacadostat, INCB057643, INCB059872; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 8
States / cities: Duarte, California • La Jolla, California • Chicago, Illinois + 4 more

Conditions: Acute Myelogenous Leukemia
Interventions: Decitabine, Vorinostat, Filgrastim (G-CSF), Fludarabine, Cytarabine; Drug
Lead sponsor: Therapeutic Advances in Childhood Leukemia Consortium; Other
Eligibility: 1 Year to 25 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 28
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 22 more

Conditions: Myelodysplastic Syndrome (MDS)
Interventions: MBG453, Azacitidine, Decitabine, INQOVI (oral decitabine); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 15
States / cities: Phoenix, Arizona • Tucson, Arizona • Denver, Colorado + 10 more

Conditions: AML - Acute Myeloid Leukemia
Interventions: Dexamethasone plus Venetoclax-based Low-Intensity Therapy; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Acute Myeloid Leukemia
Interventions: Galinpepimut-S, Azacitidine, Venetoclax, Decitabine, Cytarabine, Observation, GM-CSF, Montanide; Biological · Drug · Other
Lead sponsor: Sellas Life Sciences Group; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Angeles, California • Whittier, California + 14 more

Conditions: Myelodysplastic Syndromes
Interventions: Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Decitabine, Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine, BMS-986253, Bone Marrow Biopsy, Bone Marrow Aspiration, ECG; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions: CC-95251, Azacitidine, Venetoclax; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Los Angeles, California • Palo Alto, California • Miami, Florida + 1 more

Conditions: Graft-Versus-Host Disease(GVHD)
Interventions: 5-Azacytidine; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Head and Neck Cancer
Interventions: Oral Decitabine, Durvalumab, 5' Azacitidine, Tremelimumab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, AML, Adult, CLL, CLL, Relapsed, CLL, Refractory
Interventions: Pitavastatin, Venetoclax; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Orange, California

Conditions: COVID-19
Interventions: Decitabine, Placebo Saline; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome With Excess Blasts-2, Chronic Myelomonocytic Leukemia
Interventions: Tuspetinib, Venetoclax Oral Tablet, Azacitidine for Intravenous Infusion; Drug
Lead sponsor: Aptose Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 15
States / cities: Birmingham, Alabama • Duarte, California • Irvine, California + 12 more

About this Azacitidine clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Azacitidine as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Azacitidine.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Azacitidine clinical trials

Filter and sort this therapy

Live official records

Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)

Epigenetic Reprogramming in Relapse/Refractory AML

STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

A Phase 1B Investigator Initiated Study of Safety and Tolerability of Dexamethasone (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute Myeloid Leukemia (AML): DLIT-AML

Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

BMS-986253 in Myelodysplastic Syndromes

A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes

5-Azacytidine With Steroids for Gastrointestinal GVHD (5-AZA FOR GVHD)

Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia

Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

About this Azacitidine clinical trials directory page